Search results
Results from the WOW.Com Content Network
Particular medications can result in MRONJ, a serious but uncommon side effect in certain individuals. Such medications are frequently used to treat diseases that cause bone resorption such as osteoporosis, or to treat cancer. The main groups of drugs involved are anti-resorptive drugs, and anti-angiogenic drugs.
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
15% (50 year olds), 70% (over 80 year olds) [ 7] Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to more porous bone, and consequent increase in fracture risk. It is the most common reason for a broken bone among the elderly. [ 3]
Osteoporosis drugs taken to prevent bone fracture may cause rare, but critical, fractures of their own, the Food and Drug Administration announced today in a warning to consumers. The agency also ...
Raloxifene. Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. [ 5] For osteoporosis it is less preferred than bisphosphonates. [ 5] It is also used to reduce the risk of breast cancer in those at high risk. [ 5]
Senile osteoporosis. Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
Zoledronic acid, also known as zoledronate and sold under the brand name Zometa among others, [ 7] by Novartis among others, is a medication used to treat a number of bone diseases. [ 3] These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget's disease of bone [ 3] and Duchenne muscular dystrophy (DMD ...
A 24-week randomized trial was conducted in postmenopausal women with osteoporosis (n=222) assessing bone mass density (BMD) changes as the primary endpoint. [17] Significant BMD increase at doses of 40 and 80 mcg were found in the lumbar spine , femur and hips of abaloparatide-treated participants compared to placebo .